Eric Lefkofsky is a prominent entrepreneur and a philanthropist. He is co-founder and CEO of Tempus, a technology company known for creating a platform to fight cancer. He is also the founder of Groupon, co-founder Lightbank, Uptake Technologies, Mediaocean, InnerWorkings and Echo Global Logistics. He received his bachelor’s degree from the University of Michigan before earning his JD from the University of Michigan Law School.
Accelerated Disruption is business development moving at high technological speed. According to Lefkofsky, each day someone has a disruptive business idea that can transform the market in terms of convenience, price, functionality, service and price. However, most of these people fail to realize that the swift pace of technology allows challenges to come from both established competitors and startups. Lefkofsky argues that only the businesses that understand and control the technology forces will thrive in the future. Click Here for more.
On the other hand, entrepreneurs who cannot control the external forces will be soon displaced. According to Lefkofsky, to succeed in competitive industries, one has to choose the right sector to invest in and understand all the dynamics of the selected venture. Moreover, one should develop capital strategies to support the business during critical stages.
Lefkofsky is also involved in various philanthropic activities. In 2006, Lefkofsky and his wife founded Lefkofsky Foundation, which is committed to empowering the living standards of the people. The Foundation improves the quality of human life with a focus on human rights, healthcare, art, and education. So far Lefkofsky has donated to organizations dealing with research in the treatment of Leukemia, lung and thyroid cancer.
Tempus is a health technology company that has made its name globally for creating a platform that helps doctors offer personalized cancer treatment. With this platform, doctors are provided with genomic sequencing services helping them make real-time decisions, which are driven by data. This technology is essential in analyzing molecular and therapeutic data helping a patient to benefit from the treatment of other patients who came before.
Visit http://lefkofskyfoundation.com/about-eric-lefkofsky for more.